Overview

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Simnova Biotechnology Co.,Ltd.